CD137L-DC-EBV-VAX

Emily Nickles1, Runze Xia2, Rui Sun2

  • 1Department of Physiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore; Immunology Programme, Life Sciences Institute, National University of Singapore, Singapore, Singapore; Immunology Translational Research Programme, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.

PubMed
概括

这项研究引入了CD137L-状细胞 (DCs) 作为癌症的强效免疫疗法. 这些由单细胞生成的新型DCs在鼻癌的临床试验中显示出优异的细胞毒性反应和改善的生存率.